CU20230031A7 - Método para la detección de anticuerpos antifármaco contra anticuerpos de factor xi y/o factor xia - Google Patents

Método para la detección de anticuerpos antifármaco contra anticuerpos de factor xi y/o factor xia

Info

Publication number
CU20230031A7
CU20230031A7 CU2023000031A CU20230031A CU20230031A7 CU 20230031 A7 CU20230031 A7 CU 20230031A7 CU 2023000031 A CU2023000031 A CU 2023000031A CU 20230031 A CU20230031 A CU 20230031A CU 20230031 A7 CU20230031 A7 CU 20230031A7
Authority
CU
Cuba
Prior art keywords
factor
antibody
fxi
xia
detection
Prior art date
Application number
CU2023000031A
Other languages
English (en)
Inventor
Daniel M Bloomfield
Debra A Freedholm
Jonathan E Freeman
Royston J Glasspool
Yasser Khder
Original Assignee
Anthos Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anthos Therapeutics Inc filed Critical Anthos Therapeutics Inc
Publication of CU20230031A7 publication Critical patent/CU20230031A7/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/686—Anti-idiotype
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54306—Solid-phase reaction mechanisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54393—Improving reaction conditions or stability, e.g. by coating or irradiation of surface, by reduction of non-specific binding, by promotion of specific binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)
    • G01N2333/96441—Serine endopeptidases (3.4.21) with definite EC number
    • G01N2333/96452—Factor XI (3.4.21.27)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

<p>La presente divulgación se refiere a un método para detectar un anticuerpo antifármaco (ADA) contra un anticuerpo anti-Factor XI (FXI) o anti-Factor XIa (FXIa) o un fragmento de unión a antígeno de este, caracterizado porque el método comprende:</p> <p>a. incubar una muestra con un ácido para disociar los complejos de antígeno y anticuerpo anti-FXI o anti-FXIa o disociar complejos del ADA y del anticuerpo anti-FXI o anti-Factor XIa presentes en la muestra para formar una solución de digestión ácida,</p> <p>b. incubar la solución de igestión ácida en una placa recubierta con el anticuerpo anti-FXI o anti- XIa o un fragmento de unión a antígeno de este,</p> <p>c. neutralizar la solución de digestión ácida y</p> <p>d. detectar la presencia de los ADA mediante el uso de un cóctel de detectores rutenilados.</p> <p> </p> <p> </p>
CU2023000031A 2020-12-18 2021-12-17 Método para la detección de anticuerpos antifármaco contra anticuerpos de factor xi y/o factor xia CU20230031A7 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063127536P 2020-12-18 2020-12-18
PCT/US2021/064117 WO2022133263A1 (en) 2020-12-18 2021-12-17 Methods for the detection of anti-drug antibodies against factor xi and/or factor xia antibodies

Publications (1)

Publication Number Publication Date
CU20230031A7 true CU20230031A7 (es) 2024-02-07

Family

ID=82059801

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2023000031A CU20230031A7 (es) 2020-12-18 2021-12-17 Método para la detección de anticuerpos antifármaco contra anticuerpos de factor xi y/o factor xia

Country Status (19)

Country Link
US (1) US20240077497A1 (es)
EP (1) EP4264278A4 (es)
JP (1) JP2023554347A (es)
KR (1) KR20230121120A (es)
CN (1) CN116601491A (es)
AR (1) AR124434A1 (es)
AU (1) AU2021401421A1 (es)
CA (1) CA3199482A1 (es)
CL (1) CL2023001709A1 (es)
CO (1) CO2023008150A2 (es)
CR (1) CR20230313A (es)
CU (1) CU20230031A7 (es)
EC (1) ECSP23053645A (es)
IL (1) IL302904A (es)
JO (1) JOP20230137A1 (es)
MX (1) MX2023007281A (es)
PE (1) PE20231679A1 (es)
TW (1) TW202242414A (es)
WO (1) WO2022133263A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4555323A1 (en) * 2022-07-13 2025-05-21 Regeneron Pharmaceuticals, Inc. Mild acid immunoassays for detection of analytes

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY36751A (es) * 2015-06-26 2017-01-31 Novartis Ag Anticuerpos de factor xi y métodos de uso
EP3713965A1 (en) * 2017-11-22 2020-09-30 Novartis AG Reversal binding agents for anti-factor xi/xia antibodies and uses thereof
MX2020004921A (es) * 2017-11-29 2020-08-27 Hoffmann La Roche Ensayo de anticuerpo antifarmaco con supresion de interferencia del objetivo.
AU2020275406A1 (en) * 2019-05-13 2021-11-18 Regeneron Pharmaceuticals, Inc. Improved competitive ligand binding assays

Also Published As

Publication number Publication date
US20240077497A1 (en) 2024-03-07
MX2023007281A (es) 2023-09-04
KR20230121120A (ko) 2023-08-17
CR20230313A (es) 2023-08-18
EP4264278A4 (en) 2024-11-27
CN116601491A (zh) 2023-08-15
WO2022133263A1 (en) 2022-06-23
CL2023001709A1 (es) 2023-11-17
AU2021401421A1 (en) 2023-06-22
PE20231679A1 (es) 2023-10-19
JOP20230137A1 (ar) 2023-06-14
EP4264278A1 (en) 2023-10-25
ECSP23053645A (es) 2023-08-31
CO2023008150A2 (es) 2023-06-30
AU2021401421A9 (en) 2024-10-24
AR124434A1 (es) 2023-03-29
IL302904A (en) 2023-07-01
CA3199482A1 (en) 2022-06-23
JP2023554347A (ja) 2023-12-27
TW202242414A (zh) 2022-11-01

Similar Documents

Publication Publication Date Title
Rulander et al. Interference from anti-streptavidin antibody
NO20076662L (no) Deteksjon av et malantigen uavhengig av tilstedevaerelse eller fravaer av et korresponderende terapeutisk antistoff
MX2021005329A (es) Ensayos de luminiscencia no enzimaticos.
NZ628463A (en) Ratio based biomarkers and methods for use thereof
WO2021046316A3 (en) Anti-drug antibody assay
ATE532051T1 (de) Differenzielle reflexionsspektroskopieverfahren zur erkennung von sprengstoffen
CA2690718A1 (en) Device, kit and method for hookworm antigen capture and detection
EA202190237A1 (ru) Способы уменьшения мешающего влияния мишени лекарственного средства в иммунологическом анализе на антитела к лекарственному средству (ada)
MX2021010984A (es) Analizador de concentracion en el punto de atencion.
BR112018007842A2 (pt) imunoensaio para a detecção de cininogênio clivado de alto peso molecular, método, anticorpo isolado, kit para detectar um cininogênio de alto peso molecular clivado (hmwk)
MX357292B (es) Método para detectar cáncer.
CN102936501A (zh) 量子点-有机染料复合物关/开型镉离子比率荧光探针及其制备方法
Horn et al. Serological testing for SARS‐CoV‐2 antibodies in clinical practice: A comparative diagnostic accuracy study
AR124434A1 (es) Métodos para la detección de anticuerpos antifármaco contra anticuerpos factor xi y/o factor xia
Lee et al. Advent of innovative chemiluminescent enzyme immunoassay
US20150148249A1 (en) Method of improving the sensitivity of competitive immunoassay
Jiang et al. Simultaneous determination of gastric cancer biomarkers pepsinogen PGI/PGII using element tagged immunoassay coupled with inductively coupled plasma mass spectrometry detection
Cevirgel et al. Pre‐Vaccination Immunotypes and Immune Entropy Are Indicators of Multiple Vaccine Responsiveness
Pinder et al. Humoral and cellular responses to SARS‐CoV‐2 in patients with B‐cell haematological malignancies improve with successive vaccination
KR102659358B1 (ko) 유리 항원을 이용한 면역 검정법에서의 후크 효과 감지 방법
CN108956573A (zh) 一种检测xiap蛋白的试剂盒及其应用
US20210270833A1 (en) Biosensor for detecting influenza a virus using au-fe3o4 composite
CN105004861A (zh) 一种人嗜铬蛋白a的免疫测定法及测定试剂盒
CA3080263A1 (en) Method for diagnosing cancer from blood
Kasetsirikul et al. A paper-based immunofluorescent device for the detection of SARS-CoV-2 humanized antibody